Evinacumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), HAS (France) and NICE (England), among others, recommended or restricted evinacumab, while NYE METODER (Norway) did not recommend it.
The record spans 3 years, opening at HAS (France) on 19 Oct 2022 and running to 4 Oct 2025.
CIPM (Spain) changed its position: not recommended on 20 Mar 2024, recommended by 24 Apr 2025, after a resubmission.
No assessment is on file from PBAC (Australia), SMC (Scotland), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 15 of 16 records date from 2023 or later.
HAS (France) was first to assess evinacumab, on 19 Oct 2022; NYE METODER (Norway) did not open a file until 16 Mar 2025 — a moderate spread of 2.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 7 of 16 dated records fall in 2024 alone.
4 of the 8 agencies here assessed evinacumab more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for evinacumab.
The full ledger for evinacumab reads 10 recommended, 2 not recommended, 2 no benefit and 1 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 2 Sep 2025 | Indication extension | SMR moderate · ASMR IV | source |
| NYE METODER (Norway) | 16 Mar 2025 | Behandling av homozygot familiær hyperkolesterolemi | not introduced | source |
| NICE (England) | 11 Sep 2024 | NICE TA1002 | recommended (optimised) | source |
| G-BA (Germany) | 4 Jul 2024 | Evkeeza — benefit assessment §35a | added benefit: not proven | source |
| CIPM (Spain) | 20 Mar 2024 | Indicación terapéutica autorizada: Evkeeza está indicado como complemento a la dieta y a otros tratamientos hipolipemian… | not financed by the SNS (financed 2024-05) | source |
11 further decisions for evinacumab, across 6 agencies, are not shown here. They include the most recent record on file, 4 Oct 2025 from AIFA (Italy); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- evolocumab — same ATC class C10A — Lipid modifying agents
- alirocumab — same ATC class C10A — Lipid modifying agents
- rosuvastatin — same ATC class C10A — Lipid modifying agents
- inclisiran — same ATC class C10A — Lipid modifying agents
- ezetimibe — same ATC class C10A — Lipid modifying agents
- fenofibrate — same ATC class C10A — Lipid modifying agents
Coverage: 16 decisions for evinacumab from 8 agencies, 2022 to 2025. Data to 7 Sep 2026. ATC class C10A — Lipid modifying agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.